Vincent Forte, MD
Interventional Pain Medicine · Monroe, LANPI 1043241987
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,418 of the $5,880 with a category attached, or 75.1%. 22 manufacturers reported payments, led by Stryker at 28.3% of the total. 2025 is the largest year on record at $2,527, 4.3 times the $589 reported in 2019.
Across 150 payments — averaging $39.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$2K
- Boston Scientific$804
- Curonix LLC$634
- Nevro Corp.$537
- Medtronic$504
- Relievant Medsystems, Inc.$351
- plus $1K from 16 others
What the payments were for
- Travel & lodging$1,46225%
- Food & beverage$4,41875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 15 | $1,665 |
| Boston Scientific | 29 | $804 |
| Curonix LLC | 8 | $634 |
| Nevro Corp. | 18 | $537 |
| Medtronic(2 entities) | 10 | $504 |
| Relievant Medsystems, Inc. | 4 | $351 |
| Amgen(2 entities) | 18 | $296 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $260 |
| Vertos Medical, Inc. | 4 | $180 |
| Si-bone, Inc. | 1 | $177 |
| MML US, Inc. | 1 | $134 |
| Abbott | 5 | $95 |
| Saluda Medical Americas, Inc. | 4 | $58 |
| Daiichi Sankyo Inc. | 4 | $53 |
| Interventional Pain Technologies Inc. | 1 | $38 |
| Nalu Medical, Inc. | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| GRT US Holding, Inc. | 1 | $14 |
| Pfizer | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Assertio Therapeutics, Inc. | 1 | $11 |
| Collegium Pharmaceutical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,880 in reported general payments places this provider in the 55th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 4,692 | $98,882 |
| OxycontinOxycodone Hcl | 73 | $71,199 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,643 | $48,398 |
| RelistorMethylnaltrexone Bromide | 14 | $33,831 |
| Fentanyl | 266 | $31,293 |
| MovantikNaloxegol Oxalate | 51 | $20,606 |
| LinzessLinaclotide | 37 | $19,517 |
| Gabapentin | 1,925 | $17,994 |
| Oxycodone Hcl | 571 | $11,017 |
| Lidocaine | 55 | $8,493 |
| Xtampza ErOxycodone Myristate | 15 | $6,785 |
| Morphine Sulfate ErMorphine Sulfate | 214 | $6,697 |
| Pregabalin | 497 | $6,639 |
| Tizanidine Hcl | 997 | $5,778 |
| Diclofenac Sodium | 258 | $5,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $260 | $33,83114 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $11 | $6,78515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Monroe
- John LedbetterMonroe$4K
- Maged GuirguisNew Orleans$565K
- Suneil JollyKenner$107K
- John CefaluShreveport$71K
- Steve LeeSlidell$57K
- William WhyteShreveport$39K
- Paul HubbellMetairie$33K
- Ken EhrhardtHammond$22K
- Thomas BerryLacombe$21K
- Randall BrewerShreveport$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.